KK
PTGX icon

KLP Kapitalforvaltning’s Protagonist Therapeutics PTGX Stock Holding History

KLP Kapitalforvaltning’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.16M Buy
11,000
+400
+4% +$35.4K ﹤0.01% 951
2025
Q4 		$926K Buy
10,600
+200
+2% +$16.4K ﹤0.01% 1073
2025
Q3 		$691K Hold
10,400
– – ﹤0.01% 1241
2025
Q2 		$575K Buy
10,400
+1,700
+20% +$81.6K ﹤0.01% 1292
2025
Q1 		$421K Hold
8,700
– – ﹤0.01% 1392
2024
Q4 		$336K Buy
+8,700
New +$379K ﹤0.01% 1587

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

KLP Kapitalforvaltning's PTGX Position: Q1 2026 in Review

KLP Kapitalforvaltning increased its Protagonist Therapeutics (PTGX) stake by 3.8% in Q1 2026, buying an estimated $35.4K and bringing the position to 11,000 shares worth $1.16M. The position accounts for ﹤0.01% of the portfolio, ranked #951.

KLP Kapitalforvaltning first reported a position in PTGX in Q4 2024 and has held it in 6 quarters since. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • KLP Kapitalforvaltning held 11,000 shares of Protagonist Therapeutics worth $1.16M as of Q1 2026.
  • KLP Kapitalforvaltning bought 400 Protagonist Therapeutics shares in Q1 2026, an estimated $35.4K.
  • Protagonist Therapeutics made up ﹤0.01% of KLP Kapitalforvaltning's portfolio in Q1 2026, its #951 holding.
  • KLP Kapitalforvaltning first reported a position in Protagonist Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on KLP Kapitalforvaltning's 13F filing for Q1 2026, filed 29 Apr 2026.